Physician profile
Brian Connor
NPI 1396207684
$2,596.76
in general payments reported to CMS, 2019-2025
18 companies · $1,758 in 2025
The $1,758 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $839 · 2025: $1,758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,596.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $696.22 | 2024-2025 | |
| Genzyme Corporation | $279.20 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $260.08 | 2024-2025 | |
| Dermavant Sciences, INC. | $188.90 | 2024 | Vtama |
| Janssen Biotech, INC. | $168.07 | 2025 | Tremfya |
| Leo Pharma INC. | $160.56 | 2025 | Adbry, Anzupgo |
| Ucb, INC. | $138.92 | 2025 | Bimzelx |
| Mayne Pharma Commercial LLC | $131.21 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $114.55 | 2025 | |
| Incyte Corporation | $109.70 | 2024-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $109.40 | 2024-2025 | Dupixent |
| Galderma Laboratories, L.P. | $77.60 | 2024-2025 | Nemluvio |
| Lilly USA, LLC | $54.27 | 2024-2025 | Ebglyss, Taltz |
| Verrica Pharmaceuticals INC. | $23.98 | 2024 | Ycanth |
| Organon LLC | $23.21 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $22.99 | 2024 | |
| Arcutis Biotherapeutics, INC. | $21.93 | 2025 | Zoryve |
| Botanix Sb INC | $15.97 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Connor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.